BabU
New member
SII Seeks from DCGI Market Authorisation for India's First QHPV Vaccine Against Cervical Cancer The Pune-based firm has applied for market authorisation after completing the phase 2/3 clinical trial with support of the Department of Biotechnology to ensure its early availability in the country, they said